Tilray Nears $1B Revenue Milestone, but Profitability Remains Elusive

What happened

Tilray Brands announced it expects to achieve $1 billion in annual revenue for the current fiscal year, following an 11% increase in fiscal 2026 to approximately $911 million, driven by international cannabis expansion and the U.S. craft beer portfolio. The milestone underscores the company’s gradual top-line improvement, but recent filings reveal sharp margin compression in beverages—gross margin dropped from 40% to 31% year-over-year—and an adjusted EBITDA of just $8.4 million in Q2 FY26. Opportunities in European medical cannabis and craft beer are real, but they must overcome intense competition, a looming U.S. federal hemp THC cap that could erase hemp-derived THC products, and the company’s history of large impairments and cash burn. While the revenue target may be achievable, the path to sustainable profitability and positive free cash flow remains uncertain, leaving the stock dependent on regulatory tailwinds and execution that has yet to be proven.

Implication

Tilray’s revenue milestone reflects its diversified model gaining traction, but the numbers behind the headline warn that profitability is still a distant goal. Gross margin deterioration in beverages and the structural threat from the 0.4 mg THC cap could undermine the very growth vectors being touted. The company has repeatedly overpaid for acquisitions and relied on share issuance, diluting equity holders, and its $8.4 million adjusted EBITDA in Q2 FY26 remains heavily dependent on non-cash add-backs. Until management demonstrates sustained positive operating cash flow and net income, the stock remains a speculative bet on policy rather than an investment in a durable business. Upside from here requires flawless execution abroad and favorable regulatory changes at home—both of which are far from guaranteed.

Thesis delta

The news incrementally supports the base-case revenue trajectory but does not shift the core thesis that Tilray remains a high-risk optionality play on regulatory change. The $1 billion revenue target, while attainable, hinges on beverage and international cannabis execution that has historically disappointed. Maintain WAIT rating and attractive entry near $7.